Epithelioid hemangioendothelioma of the thyroid: a case report

Mayu Ono1,4*, Yoshio Kasuga1, Takeshi Uehara2 and Yoshinao Oda3

Abstract

Background: Epithelioid hemangioendothelioma (EHE) of the thyroid is an extremely rare disease; only three cases have been reported in the English literature to date. Here, we describe a case involving a patient with thyroid EHE successfully treated with curative surgery.

Case presentation: A 74-year-old woman presented with a right thyroid mass. The nodule was approximately 2 cm in size and was diagnosed as an indeterminate lesion by fine needle aspiration cytology. She was treated with thyroid lobectomy. The histopathological and immunohistochemical findings indicated an EHE of the thyroid. At the latest follow-up, 3 years postoperatively, the patient showed no signs of recurrence.

Conclusion: There is currently no standard therapy for EHE; however, our case suggests that curative resection represents an effective treatment.

Keywords: Epithelioid hemangioendothelioma, Thyroid, Surgery

Background

Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor, most commonly reported to occur in the lungs, liver, and bone, along with many other sites throughout the body [1]. The etiology of EHE is unknown. Previously, EHE was recognized as an intermediate-risk disease, classified between angiomatous and angiosarcoma [2]; however, in the fourth revision of the World Health Organization classification, EHE was described as a malignant vascular tumor, similar to angiosarcoma [3].

EHE of the thyroid is very rare, and only three cases have been reported to date in the English literature. Here, we describe a patient with EHE of the thyroid who underwent successful resection.

Case presentation

A 74-year-old woman was referred to our hospital because of a nodule in the right lobe of the thyroid. The nodule had been found during a medical examination performed 3 years ago, but she did not undergo a detailed examination at the local hospital at that time. On physical examination, a palpable and hard nodule of approximately 2 cm in size was noted in the right side of her neck. Results of the blood examination were normal, except for mildly increased thyroglobulin (142 ng/mL) and antithyroglobulin antibody levels (59.7 IU/mL). Ultrasonography and computed tomography showed a right thyroid nodule with calcification. The nodule had no signs of extrathyroidal invasion and measured 21 mm in diameter. The lymph nodes of the neck were not swollen (Fig. 1). The nodule was diagnosed as an indeterminate lesion by fine needle aspiration cytology. The fine needle aspiration smears showed spindle-shaped cells with prominent nucleoli and eosinophilic cytoplasm. The intercellular space was metachromatic on Giemsa staining (Fig. 2). Taken together, these findings suggested a hyalinizing trabecular adenoma, granulomatous lesion, papillary carcinoma, or poorly differentiated carcinoma.

We decided to treat this nodule as thyroid cancer. Right thyroid lobectomy and central neck dissection were performed. Macroscopically, a well-circumscribed mass in the right lobe of the thyroid was observed. Histologic evaluation of the thyroid nodule showed multinodular proliferation of oval to polygonal-shaped epithelioid cells with oval nuclei and eosinophilic cytoplasm.
arranged in sheet- or cord-like patterns, accompanied by fibrous stroma and marked osseous metaplasia. Nuclear atypia was mild, and mitosis was not prominent. Results of the immunohistochemical staining showed that these areas were partially positive for cytokeratin, cluster of differentiation (CD)34, and factor VIII; diffusely positive for vimentin; and negative for thyroglobulin, thyroid transcription factor-1, smooth muscle actin, desmin, S100, CD31, CD68, and CD163 (Fig. 3). These findings were suggestive of EHE.

Postoperatively, the patient’s thyroglobulin level fluctuated inconsistently (range, 11–292 ng/mL), as did the antithyroglobulin antibody level, although it remained positive. The mild elevation of the preoperative and postoperative thyroglobulin levels might have been caused by chronic thyroiditis. The patient has been followed-up for 3 years and has had no signs of recurrence postoperatively.

Conclusions
EHE is a rare disease, first described by Weiss et al. in 1982 [2]. The authors classified it as a vascular tumor, showing the same histological findings, but reported it as a different disease in each organ (e.g., intravascular bronchioalveolar tumor of the lung) [4]. The 2002 World Health Organization classification changed the classification of EHE from an intermediate to malignant tumor, because some malignant clinical cases had been reported in patients with EHE. EHE most commonly presents in the liver, lung, and bone [5]. The characteristics of EHE in these common sites are shown in Table 1. In addition, Table 2 summarizes the reported EHE cases from various, rare sites of the body.

Especially, EHE of the thyroid is extremely rare [6–9], with only one case reported in the Japanese literature [9], along with three in the English literature [6–8]. These cases and our present case are summarized in Table 3.

Of note, only one of the five patients was male (20%), which is in accordance with previous studies on EHE of other organs, in which most patients were women (male to female ratio, 1:4) [1]. There was no predominance in age (range, 35–74 years) or tumor size (range 2.1–8 cm), but all patients had a single nodule of the thyroid. On the other hand, EHE of other organs associated with multiple organ involvement in 36% of cases [5].
There have been several discussions on the prognostic factors of EHE, such as the presence of pulmonary lesions, multorgan involvement, age, and sex [1]. In addition, mitotic activity (>3 mitotic figures/50 high-power fields) and size (>3.0 cm) have been reported as risk factors for mortality in cases of EHE of the soft tissues [10]. Although the thyroid EHE patient with the largest tumor (80 mm) died 13 months after the diagnosis [7], the other patients, whose tumor sizes were all <4 cm, had uneventful outcomes [6, 8, 9].

There is no standard treatment for EHE, although curative resection has been reported as a successful treatment with good outcomes [1]. All five patients with thyroid EHE underwent surgery. For this site, total resection can be relatively easily performed, whereas this treatment is unlikely to be performed for EHEs of other organs such as the liver, bone, and lungs. However, it is difficult to maintain a sufficient surgical margin in cases of large thyroid tumors. Our patient had the smallest tumor of the five cases, and no signs of adhesion, extrathyroidal extension, and lymph node metastasis. As mentioned above, the previously reported patient with the largest tumor experienced local recurrence and died. That tumor showed adhesion, whereas pathologically,
there was no evidence of a residual tumor [7]. These findings suggest that tumor size is likely an important factor for the effectiveness of curative resection for thyroid EHE. Further studies are needed to determine the optimal surgical margin and whether lymph node dissection is sufficient for curative surgery. Moreover, two patients received radiation therapy because of lymph node metastasis. Radiation therapy may be effective to control local recurrences; however, this could not be confirmed, because the follow-up periods in the past cases were short.

Finally, the presence of CAMTA1-WWTR1 gene fusion in EHE was recently demonstrated [11]. This abnormality has been reported in the majority of EHEs at various anatomical sites, while it is absent in other epithelioid vascular tumors [11–13]. It was also confirmed in one case of thyroid EHE [8]. Therefore, fluorescence in situ hybridization analysis to detect CAMTA-

Table 1 Characteristics of epithelioid hemangioendothelioma (EHE) in the liver, lungs, soft tissues, and bone (common presentations)

| Site [ref] | Sex | Multicentric | Metastasis | Management | Survival rate (5 years) | Prognostic factors | Treatment |
|------------|-----|--------------|------------|------------|-------------------------|-------------------|-----------|
| Liver [14–19] | M < F | 87% | 36.6 | Lungs, peritoneum, lymph nodes, bone | Transplantation, resection, medication, radiotherapy, embolization | 41 | Extrahepatic disease, vascular invasion | Chemotherapy (doxorubicin, cisplatin, 5FU), targeted therapy (sorafenib, pazopanib), IFN α-2b, thalidomide, lenalidomide |
| Lung [1, 20–23] | M < F | 91% | 50.5 | Liver, pleura, lymph nodes | Lung resection, medication | 60 | Hemothysis, pleural effusion, anemia, thoracic symptoms | Chemotherapy (carboplatin, paclitaxel), targeted therapy (bevacizumab, pazopanib), IFN α-2b, thalidomide, lenalidomide |
| Soft tissue [10, 24] | M < F | 4% | 22 | Lungs, lymph nodes, liver, bone | Surgical resection, chemotherapy, radiotherapy | 81 | Mitotic activity, size | ND |
| Bone [25–27] | M > F >50% | ND | Uncommon | Wide surgical resection, limited surgery, radiofrequency ablation, radiotherapy | | 92 (10 years) | Visceral involvement | |

M male, F female, 5FU 5-fluorouracil, IFN interferon, ND not determined

Table 2 Summary of previously reported cases of epithelioid hemangioendothelioma (EHE) occurring in rare sites

| Author [ref] | Site | Treatment | Metastasis/recurrence | Outcome (follow-up period) |
|--------------|------|-----------|-----------------------|----------------------------|
| Barger [28] | Brain | Resection (this case), chemotherapy, radiotherapy, gamma knife, sunitinib | (−)/ND | Alive (1 month) |
| Sancheti [29] | Hypopharynx | Excision | (−)/(−) | Alive (1 year) |
| Boscaino [30] | Larynx | Resection | ND/ND | ND |
| Pigadas [31] | Parotid salivary gland | Parotidectomy | (−)/(−) | Alive (18 months) |
| Moulai [32] | Heart | Chemotherapy, cardiac transplantation | (−)/(+ 2 years) | Alive (10 years) |
| Traverse [33] | Aorta | Resection | (−)/(−) | ND |
| Charette [34] | Vein | Resection | (−)/(−) | Alive (18 months) |
| Versaci [35] | Stomach | Resection | (−)/(−) | Alive (8 months) |
| Ratan [36] | Greater omentum | Resection | (−)/(−) | Alive (6 years) |
| Bozkurt [37] | Adrenal gland | Laparoscopic excision | (−)/(−) | Alive (6 months) |
| Tolkaich [38] | Kidney | Nephrectomy, sunitinib | (−)/(+ 2 m) | Dead (33 months) |
| Liu [39] | Bladder | Transurethral resection | (−)/(−) | Alive (6 months) |
| Elhosseiny [40] | Penis | Local excision | (−)/(−) | Alive (ND) |
| Illueca [41] | Ovary | Resection | (−)/(−) | Alive (1 year) |
WWTR1 fusion may become a definite tool for the diagnosis of EHE in the future. In conclusion, EHE of the thyroid is an extremely rare disease. Its clinical course varies, and the prognostic factors are unclear. Curative resection may be an effective treatment, but surgical issues such as the appropriate extent of the surgical margin and use of lymph node dissection remain to be clarified. Further studies are needed to analyze the etiology of EHE and to determine the optimal treatment.

Abbreviations
CD: Cluster of differentiation; EHE: Epithelioid hemangioendothelioma

Authors’ contributions
MO drafted the manuscript. YK and MO performed the surgery and postoperative management. YK and TU revised the manuscript. TU and YO performed the pathological diagnosis. All authors read and approved the final manuscript.

Authors’ information
MO and YK are surgeons at the Department of Breast and Endocrine Surgery, Nagano Matsushiro General Hospital. YK is the general director of Nagano Matsushiro General Hospital. TU is an associate professor at the Department of Laboratory Medicine, Shinshu University School of Medicine. YO is a professor at the Department of Anatomic Pathology, Pathological Sciences, Kyushu University.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Author details
1Department of Breast and Endocrine Surgery, Nagano Matsushiro General Hospital, 183 Matsushiro, Nagano 381-1231, Japan. 2Department of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan. 3Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. *Present address: Department of Breast and Endocrine Surgery, Iida Municipal Hospital, 438 Yawamatamachi, Iida 812-8582, Japan.

Received: 1 November 2016 Accepted: 24 January 2017

Table 3 Cases of thyroid epithelioid hemangioendothelioma (EHE)

| Author/year | Age (years) | Sex | Thyroid tumor Location | Surgical procedure | Metastasis | Adjuvant therapy | Recurrence | Outcome (follow-up period) |
|-------------|-------------|-----|-------------------------|--------------------|------------|------------------|------------|---------------------------|
| Fujiwara/1998 [9] | 56 | M | Left lobe | Lobectomy | Lymph node | Radiation | (−) | Alive (11 months) |
| Siddiqui/1998 [6] | 44 | F | Right lobe | Lobectomy | Unknown | Unknown | (−) | − | Alive (24 months) |
| Hassan/2005 [7] | 73 | F | Right lobe | Total thyroidectomy | Unknown | IFN-α | (+) | 9 months | Dead (13 months) |
| Shah/2016 [8] | 35 | F | Left lobe | Total thyroidectomy | Lymph node | Plans for radiation and chemotherapy | (−) | − | Alive (4 months) |
| Our case/2016 | 74 | F | Right lobe | Lobectomy | Central | (−) | (−) | − | Alive (36 months) |

M male, F female

References
1. Sardaro A, Bardosca L, Petruzelli MF, Portaliu M. Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncol Rev. 2014;8:259.
2. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: A vascular tumor often mistaken for a carcinoma. Cancer. 1982;50:970–81.
3. Fletcher CD, Hogendoorn P, Mertens F, Bridge J. WHO Classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.
4. Dal DH, Liebow AA. Intravascular bronchioloalveolar tumor. Am J Pathol. 1973;78A–7a.
5. Lau K, Massad M, Pollak C, Rubin C, Yeh J, Wang J, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest. 2011;140:1312–8.
6. Siddiqui MT, Evans HL, Ro JY, Ayala AG. Epithelioid haemangioendothelioma of the thyroid gland: a case report and review of literature. Histopathology. 1998;32:473–6.
7. Hassan I, Barth P, Celik I, Hoffmann S, Langer P, Ramassamy A, et al. An authentic malignant epithelioid hemangioendothelioma of the thyroid: a case report and review of the literature. Thyroid. 2005;15:1377–81.
8. Shah AA, Ohori NP, Yip L, Coyne C, Antonescu CR, Seethala RR. Epithelioid hemangioendothelioma: a rare primary thyroid tumor with confirmation of WWTR1 and CAMTA1 rearrangements. Endocr Pathol. 2016;27:147–52.
9. Fujiwara K, Miura M. Epithelioid hemangioendothelioma of the thyroid gland: a case report. Pract Otorhinolaryngol. 1998;91:196–8.
10. Deyrup AT, Tigliouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol. 2008;32:924–7.
11. Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50:644–53.
12. Anderson T, Zhang L, Hameed M, Rustch V, Travis WD, Antonescu CR. Thoracic epithelioid malignant vascular tumors: A clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am J Surg Pathol. 2015;39:132–9.
13. Flucke U, Vogels RJ, de Saint Aubain Somerhausen N, Creytsen DH, Riedl RG, van Gorp JM, et al. Epithelioid hemangioendothelioma: clinicopathologic, immunohistochemical, and molecular genetic analysis of 39 cases. Diagn Pathol. 2014;9:131.
14. Mehdabi A, Kashi F, Fonouni H, Schmierer P, Schmied BM, Hallsemiedt P, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107:2108–21.
15. Cardinal J, de Vera ME, Marsh JW, Steel JL, Geller DA, Fontes P, et al. Treatment of hepatic epithelioid hemangioendothelioma: a single-institution experience with 25 cases. Arch Surg. 2009;144:1035–9.
16. Lerut JP, Orlando G, Adam R, Schiavo M, Klempnauer J, Mirza D, et al. The place of liver transplantation in the treatment of hepatic epithelioid hemangioendothelioma: report of the European liver transplant registry. Ann Surg. 2007;246:949–57.
17. Sangoi A, Itanairaequi M, Fernández-Ros N. Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib. Rare Tumors. 2012;4:e34.
18. Salech F, Valderrama S, Nervi B, Rodriguez JC, Oksenberg D, Koch A, et al. Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. Ann Hepatol. 2011;10:99–102.
19. Bally O, Tassy L, Richioud B, Decouvelaere AV, Blay JY, Derbel O. Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma. Clin Sarcoma Res. 2015;5:12.
20. Bagan P, Hassan M, Barthes FLP, Peyrard S, Soullamas R, Daniel C, et al. Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature. Ann Thorac Surg. 2006;82:2010–3.
21. Amin R, Hiroshima K, Kokubo T, Nishikawa M, Narita M, Kuroki M, et al. Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report. Respirology. 2006;11:818–25.
22. Ye B, Li W, Feng J, Shi JX, Chen Y, Han BH. Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: report of three cases and review of the literature. Oncol Lett. 2013;5:1491–6.
23. Semeniuc V, Naroditsky I, Keidar Z, Bar-Sela G. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options. BMC Cancer. 2015;15:402.
24. Mintzel T, Beham A, Calonje E, Katenkamp D, Fletcher C. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol. 1997;21:363–74.
25. Kleer CG, Unni KK, McLeod RA. Epithelioid hemangioendothelioma of bone. Am J Surg Pathol. 1996;20:1301–11.
26. Larochelle O, Périgny M, Lagacé R, Dion N, Giguère C. Epithelioid hemangioendothelioma of bone. Radiographics. 2006;26:265–70.
27. Angelini A, Mavrogenis AF, Gambaretto M, Merlino B, Pici P, Ruggieri P. Surgical treatment and result of 62 patients with epithelioid hemangioendothelioma of bone. J Surg Oncol. 2014;109:791–7.
28. Barger J, Tanweer O, Liebty B, Snuderl M, Jafar JJ. Suprasellar epithelioid hemangioendothelioma: case report and review of the literature. Surg Neurol Int. 2016;7:5596–602.
29. Sancheti S, Singh JH, Malik A, Devi KT, Jain S. Epithelioid hemangioendothelioma of hypopharynx: a rare presentation. Indian J Dent. 2016;7:109–11.
30. Boscaino A, Errico ME, Orabona P, Tornillo L, Staibano S, Donofrio V, et al. Epithelioid hemangioendothelioma of the larynx. Tumori. 1999;85:515–8.
31. Pigadas N, Mohamid W, McDermott P. Epithelioid hemangioendothelioma of the parotid salivary gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;89:730–9.
32. Moulai N, Chavanon O, Guillou L, Noirclerc M, Blin D, Brambilla E, et al. Atypical primary epithelioid hemangioendothelioma of the heart. J Thorac Oncol. 2006;1:188–9.
33. Traverse JH, Lesser JR, Flygenring BP, Bracken TH, Olevsky OM, Nicollof DM, et al. Epithelioid hemangioendothelioma of the thoracic aorta resulting in aortic obstruction and congestive heart failure. Circulation. 1999;100:564–5.
34. Charette S, Nehler MR, Whitehill TA, Gibbs P, Fouli D, Krupski WC. Epithelioid hemangioendothelioma of the common femoral vein: case report and review of the literature. J Vasc Surg. 2001;33:1100–3.
35. Versaci A, Macri A, Scuderi G, Leoneilo G, Fedele F, Cetto A, et al. Epithelioid hemangioendothelioma of the stomach: clinical-pathological features, nosologic setting, and surgical therapy. Report of a case Surg Today. 2002;32:274–7.
36. Ratan S, Bhatnagar V, Gupta SD, Mitra DK. Epithelioid hemangioendothelioma of the greater omentum: report of a case. Surg Today. 1999;29:919–21.
37. Bozkurt O, Demir Ö, Yener S, Tuna B, Seçil M, Yörükoglu K. Malignant epithelioid hemangioendothelioma of the adrenal gland treated by laparoscopic excision. Urology. 2015;85:15–6.
38. Tolkach Y, Petrov S, Lerut E, Van Poppel H. Epithelioid hemangioendothelioma of the kidney treated with sunitinib. Onkologie. 2012;35:376–8.
39. Liu B, Zhang C, Zhang Q, Liu G, Ma Z, Qi J, et al. Primary epithelioid hemangioendothelioma of the bladder: case report and review of the literature. Urol Int. 2015;94:240–3.
40. Ehossenyy AA, Ramaswamy G, Healy RO. Epithelioid hemangioendothelioma of penis. Urology. 1986;28:243–5.
41. Ilueca C, Machado I, Garcia A, Covisa A, Morales J, Cruz J, et al. Uncommon vascular tumor of the ovary. Primary ovarian epithelioid hemangioendothelioma or vascular sarcomatous transformation in ovarian germ cell tumor? Arch Gynecol Obstet. 2011;284:1589–91.